FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:GRIK4-SESN1

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: GRIK4-SESN1
FusionPDB ID: 34796
FusionGDB2.0 ID: 34796
HgeneTgene
Gene symbol

GRIK4

SESN1

Gene ID

2900

27244

Gene nameglutamate ionotropic receptor kainate type subunit 4sestrin 1
SynonymsEAA1|GRIK|GluK4|KA1PA26|SEST1
Cytomap

11q23.3

6q21

Type of geneprotein-codingprotein-coding
Descriptionglutamate receptor ionotropic, kainate 4excitatory amino acid receptor 1glutamate receptor KA1glutamate receptor, ionotropic, kainate 4sestrin-1p53 activated gene 26p53 regulated PA26 nuclear protein
Modification date2020032020200313
UniProtAcc

Q16099

Main function of 5'-partner protein: FUNCTION: Receptor for glutamate. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. The postsynaptic actions of Glu are mediated by a variety of receptors that are named according to their selective agonists.
.
Ensembl transtripts involved in fusion geneENST idsENST00000438375, ENST00000527524, 
ENST00000527130, 
ENST00000302071, 
ENST00000356644, ENST00000517548, 
ENST00000436639, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score6 X 6 X 5=1806 X 6 X 3=108
# samples 66
** MAII scorelog2(6/180*10)=-1.58496250072116
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(6/108*10)=-0.84799690655495
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: GRIK4 [Title/Abstract] AND SESN1 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: GRIK4 [Title/Abstract] AND SESN1 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)GRIK4(120745952)-SESN1(109323546), # samples:2
Anticipated loss of major functional domain due to fusion event.GRIK4-SESN1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
GRIK4-SESN1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
GRIK4-SESN1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
GRIK4-SESN1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID


check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr11:120745952/chr6:109323546)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across GRIK4 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across SESN1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000527524GRIK4chr11120745952+ENST00000436639SESN1chr6109323546-393514512872827846
ENST00000438375GRIK4chr11120745952+ENST00000436639SESN1chr6109323546-399015063422882846

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000527524ENST00000436639GRIK4chr11120745952+SESN1chr6109323546-0.0009022790.9990977
ENST00000438375ENST00000436639GRIK4chr11120745952+SESN1chr6109323546-0.000737710.9992623

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for GRIK4-SESN1

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
GRIK4chr11120745952SESN1chr61093235461451388LKILQFTRNGFRQELGIRIPRPLGQG
GRIK4chr11120745952SESN1chr61093235461506388LKILQFTRNGFRQELGIRIPRPLGQG

Top

Potential FusionNeoAntigen Information of GRIK4-SESN1 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
GRIK4-SESN1_120745952_109323546.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
GRIK4-SESN1chr11120745952chr61093235461506HLA-B13:02RQELGIRI0.98970.68981119
GRIK4-SESN1chr11120745952chr61093235461506HLA-B52:01RQELGIRI0.6960.9791119
GRIK4-SESN1chr11120745952chr61093235461506HLA-B27:02FRQELGIRI0.99930.59811019
GRIK4-SESN1chr11120745952chr61093235461506HLA-B27:05FRQELGIRI0.99920.84871019
GRIK4-SESN1chr11120745952chr61093235461506HLA-B27:04TRNGFRQEL0.9990.8259615
GRIK4-SESN1chr11120745952chr61093235461506HLA-B27:04FRQELGIRI0.9990.72031019
GRIK4-SESN1chr11120745952chr61093235461506HLA-B39:24TRNGFRQEL0.99890.7723615
GRIK4-SESN1chr11120745952chr61093235461506HLA-B27:07TRNGFRQEL0.99870.6656615
GRIK4-SESN1chr11120745952chr61093235461506HLA-B27:02TRNGFRQEL0.99870.5774615
GRIK4-SESN1chr11120745952chr61093235461506HLA-B39:01TRNGFRQEL0.99850.9632615
GRIK4-SESN1chr11120745952chr61093235461506HLA-B39:24FRQELGIRI0.99850.67511019
GRIK4-SESN1chr11120745952chr61093235461506HLA-B27:05TRNGFRQEL0.99830.7683615
GRIK4-SESN1chr11120745952chr61093235461506HLA-B39:06TRNGFRQEL0.99790.91615
GRIK4-SESN1chr11120745952chr61093235461506HLA-B14:01TRNGFRQEL0.99780.966615
GRIK4-SESN1chr11120745952chr61093235461506HLA-B14:02TRNGFRQEL0.99780.966615
GRIK4-SESN1chr11120745952chr61093235461506HLA-B39:06FRQELGIRI0.99770.77521019
GRIK4-SESN1chr11120745952chr61093235461506HLA-B38:01TRNGFRQEL0.99650.9842615
GRIK4-SESN1chr11120745952chr61093235461506HLA-B38:02TRNGFRQEL0.99640.9842615
GRIK4-SESN1chr11120745952chr61093235461506HLA-B39:01FRQELGIRI0.98940.9551019
GRIK4-SESN1chr11120745952chr61093235461506HLA-B38:01FRQELGIRI0.9860.97921019
GRIK4-SESN1chr11120745952chr61093235461506HLA-B38:02FRQELGIRI0.98220.98151019
GRIK4-SESN1chr11120745952chr61093235461506HLA-B15:10TRNGFRQEL0.9530.743615
GRIK4-SESN1chr11120745952chr61093235461506HLA-B15:37TRNGFRQEL0.9130.8122615
GRIK4-SESN1chr11120745952chr61093235461506HLA-B15:18TRNGFRQEL0.86110.8642615
GRIK4-SESN1chr11120745952chr61093235461506HLA-B07:10TRNGFRQEL0.19170.5558615
GRIK4-SESN1chr11120745952chr61093235461506HLA-A31:02RQELGIRIPR0.95760.66481121
GRIK4-SESN1chr11120745952chr61093235461506HLA-A31:06RQELGIRIPR0.84190.55121121
GRIK4-SESN1chr11120745952chr61093235461506HLA-B27:07GFRQELGIRI0.79980.6031919
GRIK4-SESN1chr11120745952chr61093235461506HLA-B27:14FRQELGIRI0.99930.81071019
GRIK4-SESN1chr11120745952chr61093235461506HLA-B27:14TRNGFRQEL0.99860.7249615
GRIK4-SESN1chr11120745952chr61093235461506HLA-B39:09TRNGFRQEL0.99850.8887615
GRIK4-SESN1chr11120745952chr61093235461506HLA-B39:12TRNGFRQEL0.99810.9662615
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:05TRNGFRQEL0.9980.9719615
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:95TRNGFRQEL0.99750.8133615
GRIK4-SESN1chr11120745952chr61093235461506HLA-B39:05TRNGFRQEL0.99580.9595615
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:27TRNGFRQEL0.99570.9705615
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:95FRQELGIRI0.99470.77381019
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:13TRNGFRQEL0.99450.9639615
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:05FRQELGIRI0.99430.97581019
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:29TRNGFRQEL0.99420.9576615
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:27FRQELGIRI0.99210.96761019
GRIK4-SESN1chr11120745952chr61093235461506HLA-B39:12FRQELGIRI0.98560.95721019
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:29FRQELGIRI0.97140.9511019
GRIK4-SESN1chr11120745952chr61093235461506HLA-B27:03FRQELGIRI0.96030.86011019
GRIK4-SESN1chr11120745952chr61093235461506HLA-B27:03TRNGFRQEL0.95640.7822615
GRIK4-SESN1chr11120745952chr61093235461506HLA-B73:01FRQELGIRI0.95080.68351019
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:46TRNGFRQEL0.94120.9463615
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:46FRQELGIRI0.94090.92721019
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:19FRQELGIRI0.94040.82771019
GRIK4-SESN1chr11120745952chr61093235461506HLA-B73:01TRNGFRQEL0.93550.8963615
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:10FRQELGIRI0.93410.97161019
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:80FRQELGIRI0.93160.96211019
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:67FRQELGIRI0.93160.96211019
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:19TRNGFRQEL0.91310.8583615
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:67TRNGFRQEL0.90920.9723615
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:80TRNGFRQEL0.90920.9723615
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:10TRNGFRQEL0.89240.9755615
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:13FRQELGIRI0.82480.9491019
GRIK4-SESN1chr11120745952chr61093235461506HLA-B14:03TRNGFRQEL0.72540.9439615
GRIK4-SESN1chr11120745952chr61093235461506HLA-C12:16TRNGFRQEL0.34630.9745615
GRIK4-SESN1chr11120745952chr61093235461506HLA-C12:16FRQELGIRI0.00970.96021019
GRIK4-SESN1chr11120745952chr61093235461506HLA-C12:16FTRNGFRQEL0.9950.9727515
GRIK4-SESN1chr11120745952chr61093235461506HLA-B73:01FRQELGIRIP0.98270.75821020
GRIK4-SESN1chr11120745952chr61093235461506HLA-A31:01RQELGIRIPR0.96820.60861121
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:05FTRNGFRQEL0.9130.96515
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:27FTRNGFRQEL0.82840.966515
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:95FTRNGFRQEL0.78560.7785515
GRIK4-SESN1chr11120745952chr61093235461506HLA-B39:12FTRNGFRQEL0.47580.9547515
GRIK4-SESN1chr11120745952chr61093235461506HLA-B27:06TRNGFRQEL0.99930.8476615
GRIK4-SESN1chr11120745952chr61093235461506HLA-B27:08FRQELGIRI0.99920.7271019
GRIK4-SESN1chr11120745952chr61093235461506HLA-B27:09FRQELGIRI0.9990.85271019
GRIK4-SESN1chr11120745952chr61093235461506HLA-B27:10TRNGFRQEL0.9990.8939615
GRIK4-SESN1chr11120745952chr61093235461506HLA-B27:10FRQELGIRI0.99890.80561019
GRIK4-SESN1chr11120745952chr61093235461506HLA-B27:06FRQELGIRI0.99890.74541019
GRIK4-SESN1chr11120745952chr61093235461506HLA-B27:09TRNGFRQEL0.99870.763615
GRIK4-SESN1chr11120745952chr61093235461506HLA-B27:08TRNGFRQEL0.99860.7111615
GRIK4-SESN1chr11120745952chr61093235461506HLA-B39:31TRNGFRQEL0.99860.9632615
GRIK4-SESN1chr11120745952chr61093235461506HLA-B39:02TRNGFRQEL0.99840.9809615
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:01TRNGFRQEL0.99750.7965615
GRIK4-SESN1chr11120745952chr61093235461506HLA-B38:05TRNGFRQEL0.99650.9842615
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:01FRQELGIRI0.9960.79041019
GRIK4-SESN1chr11120745952chr61093235461506HLA-C06:08TRNGFRQEL0.99250.9941615
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:17TRNGFRQEL0.99220.9758615
GRIK4-SESN1chr11120745952chr61093235461506HLA-B39:31FRQELGIRI0.99090.95421019
GRIK4-SESN1chr11120745952chr61093235461506HLA-B38:05FRQELGIRI0.9860.97921019
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:04TRNGFRQEL0.9720.9276615
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:22TRNGFRQEL0.93850.8335615
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:02FRQELGIRI0.93160.96211019
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:02TRNGFRQEL0.90920.9723615
GRIK4-SESN1chr11120745952chr61093235461506HLA-B15:09TRNGFRQEL0.90670.9605615
GRIK4-SESN1chr11120745952chr61093235461506HLA-B39:11TRNGFRQEL0.86120.9051615
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:04FRQELGIRI0.83520.94431019
GRIK4-SESN1chr11120745952chr61093235461506HLA-C06:08FRQELGIRI0.80580.98841019
GRIK4-SESN1chr11120745952chr61093235461506HLA-C03:67TRNGFRQEL0.78970.9856615
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:22FRQELGIRI0.75210.83081019
GRIK4-SESN1chr11120745952chr61093235461506HLA-C06:06TRNGFRQEL0.58290.992615
GRIK4-SESN1chr11120745952chr61093235461506HLA-C06:17TRNGFRQEL0.33180.9962615
GRIK4-SESN1chr11120745952chr61093235461506HLA-C06:02TRNGFRQEL0.33180.9962615
GRIK4-SESN1chr11120745952chr61093235461506HLA-C06:06FRQELGIRI0.30030.98741019
GRIK4-SESN1chr11120745952chr61093235461506HLA-C06:17FRQELGIRI0.03390.99041019
GRIK4-SESN1chr11120745952chr61093235461506HLA-C06:02FRQELGIRI0.03390.99041019
GRIK4-SESN1chr11120745952chr61093235461506HLA-C06:02FTRNGFRQEL0.99440.9964515
GRIK4-SESN1chr11120745952chr61093235461506HLA-C06:17FTRNGFRQEL0.99440.9964515
GRIK4-SESN1chr11120745952chr61093235461506HLA-B27:06FTRNGFRQEL0.94450.7467515
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:22FTRNGFRQEL0.93090.8449515
GRIK4-SESN1chr11120745952chr61093235461506HLA-C06:08FTRNGFRQEL0.86070.9935515
GRIK4-SESN1chr11120745952chr61093235461506HLA-B27:09GFRQELGIRI0.82850.6347919
GRIK4-SESN1chr11120745952chr61093235461506HLA-C07:01FTRNGFRQEL0.80150.7685515

Top

Potential FusionNeoAntigen Information of GRIK4-SESN1 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
GRIK4-SESN1_120745952_109323546.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0101RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0101TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0101NGFRQELGIRIPRPL823
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0101FTRNGFRQELGIRIP520
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0103RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0103TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0103NGFRQELGIRIPRPL823
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0105RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0105TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0105NGFRQELGIRIPRPL823
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0105FTRNGFRQELGIRIP520
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0107RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0107TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0107NGFRQELGIRIPRPL823
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0107FTRNGFRQELGIRIP520
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0109RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0109TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0109NGFRQELGIRIPRPL823
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0109FTRNGFRQELGIRIP520
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0111RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0111TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0111NGFRQELGIRIPRPL823
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0111FTRNGFRQELGIRIP520
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0113RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0113TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0113NGFRQELGIRIPRPL823
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0113FTRNGFRQELGIRIP520
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0115RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0115TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0115NGFRQELGIRIPRPL823
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0115FTRNGFRQELGIRIP520
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0117RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0117TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0117NGFRQELGIRIPRPL823
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0117FTRNGFRQELGIRIP520
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0119RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0119TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0119NGFRQELGIRIPRPL823
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0119FTRNGFRQELGIRIP520
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0121RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0121TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0121NGFRQELGIRIPRPL823
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0121FTRNGFRQELGIRIP520
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0125RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0125TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0125NGFRQELGIRIPRPL823
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0125FTRNGFRQELGIRIP520
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0127RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0127TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0127NGFRQELGIRIPRPL823
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0127FTRNGFRQELGIRIP520
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0129RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0129TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0129NGFRQELGIRIPRPL823
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0129FTRNGFRQELGIRIP520
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0131RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0131TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0131NGFRQELGIRIPRPL823
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0131FTRNGFRQELGIRIP520
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0338RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0704RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0704TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0704FTRNGFRQELGIRIP520
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0704NGFRQELGIRIPRPL823
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0706RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0709RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0711RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0711TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0711FTRNGFRQELGIRIP520
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0819RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-0905RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1222RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1222TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1304LKILQFTRNGFRQEL015
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1317LKILQFTRNGFRQEL015
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1343LKILQFTRNGFRQEL015
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1393LKILQFTRNGFRQEL015
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1416LKILQFTRNGFRQEL015
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1448RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1511RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1511TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1515RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1515TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1527RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1527TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1529RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1531RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1534RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1534TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1601RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1601TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1602RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1602TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1603RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1603TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1604RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1604TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1605RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1605TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1607RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1607TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1608RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1608TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1609RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1609TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1610RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1610TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1611RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1611TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1612RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1612TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1614RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1614TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1616RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB1-1616TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB3-0109RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB3-0109TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB3-0209RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB3-0209TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB3-0221RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB3-0221TRNGFRQELGIRIPR621
GRIK4-SESN1chr11120745952chr61093235461506DRB3-0303RNGFRQELGIRIPRP722
GRIK4-SESN1chr11120745952chr61093235461506DRB3-0303TRNGFRQELGIRIPR621

Top

Fusion breakpoint peptide structures of GRIK4-SESN1

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
9605TRNGFRQELGIRIPGRIK4SESN1chr11120745952chr61093235461506

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of GRIK4-SESN1

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN9605TRNGFRQELGIRIP-7.15543-7.26883
HLA-B14:023BVN9605TRNGFRQELGIRIP-4.77435-5.80965
HLA-B52:013W399605TRNGFRQELGIRIP-6.80875-6.92215
HLA-B52:013W399605TRNGFRQELGIRIP-4.20386-5.23916
HLA-A11:014UQ29605TRNGFRQELGIRIP-7.5194-8.5547
HLA-A11:014UQ29605TRNGFRQELGIRIP-6.9601-7.0735
HLA-A24:025HGA9605TRNGFRQELGIRIP-7.52403-7.63743
HLA-A24:025HGA9605TRNGFRQELGIRIP-5.82433-6.85963
HLA-B27:056PYJ9605TRNGFRQELGIRIP-3.28285-4.31815
HLA-B44:053DX89605TRNGFRQELGIRIP-5.91172-6.94702
HLA-B44:053DX89605TRNGFRQELGIRIP-4.24346-4.35686

Top

Vaccine Design for the FusionNeoAntigens of GRIK4-SESN1

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
GRIK4-SESN1chr11120745952chr61093235461019FRQELGIRITTTCGGCAGGAACTTGGCATTAGAATT
GRIK4-SESN1chr11120745952chr61093235461020FRQELGIRIPTTTCGGCAGGAACTTGGCATTAGAATTCCT
GRIK4-SESN1chr11120745952chr61093235461119RQELGIRICGGCAGGAACTTGGCATTAGAATT
GRIK4-SESN1chr11120745952chr61093235461121RQELGIRIPRCGGCAGGAACTTGGCATTAGAATTCCTCGA
GRIK4-SESN1chr11120745952chr6109323546515FTRNGFRQELTTCACAAGGAATGGTTTTCGGCAGGAACTT
GRIK4-SESN1chr11120745952chr6109323546615TRNGFRQELACAAGGAATGGTTTTCGGCAGGAACTT
GRIK4-SESN1chr11120745952chr6109323546919GFRQELGIRIGGTTTTCGGCAGGAACTTGGCATTAGAATT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
GRIK4-SESN1chr11120745952chr6109323546015LKILQFTRNGFRQELTTGAAAATCTTACAGTTCACAAGGAATGGTTTTCGGCAGGAACTT
GRIK4-SESN1chr11120745952chr6109323546520FTRNGFRQELGIRIPTTCACAAGGAATGGTTTTCGGCAGGAACTTGGCATTAGAATTCCT
GRIK4-SESN1chr11120745952chr6109323546621TRNGFRQELGIRIPRACAAGGAATGGTTTTCGGCAGGAACTTGGCATTAGAATTCCTCGA
GRIK4-SESN1chr11120745952chr6109323546722RNGFRQELGIRIPRPAGGAATGGTTTTCGGCAGGAACTTGGCATTAGAATTCCTCGACCA
GRIK4-SESN1chr11120745952chr6109323546823NGFRQELGIRIPRPLAATGGTTTTCGGCAGGAACTTGGCATTAGAATTCCTCGACCACTA

Top

Information of the samples that have these potential fusion neoantigens of GRIK4-SESN1

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
OVGRIK4-SESN1chr11120745952ENST00000438375chr6109323546ENST00000436639TCGA-04-1514-01A

Top

Potential target of CAR-T therapy development for GRIK4-SESN1

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to GRIK4-SESN1

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to GRIK4-SESN1

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource